{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T11:18:16Z","timestamp":1788347896348,"version":"build-2803163510"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) infection remains a major cause of morbidity and mortality after allogeneic stem cell transplantation (aSCT). In 2012, the UK Advisory Committee for the Safety of Tissues and Organs (SaBTO) recommended that CMV\u2010unselected (CMV\u2010U) blood components could be safely transfused to this population without increasing the risk of transfusion\u2010transmitted CMV (TTI\u2010CMV). A 2015 survey of UK transplant centres found that 22.7% of aSCT centres did not follow this recommendation. In response, a subsequent good practice paper addressed concerns regarding the determination of pre\u2010transplant CMV serostatus. Annual Serious Hazards of Transfusion (SHOT) reports continue to reassure, with no emerging safety concerns linked to the increased use of CMV\u2010U blood components in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To clarify changes in English practice regarding the provision of CMV\u2010U blood components for potential allogeneic stem cell recipients and to identify factors contributing to the continued use of CMV\u2010seronegative (CMV\u2010N) blood components outside SaBTO recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We surveyed English aSCT centres to establish current practices and perceptions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 32 English transplant centres, 28 responded (88%), 19 adult and nine paediatric centres; 10.7% continue to provide CMV\u2010N components to all CMV\u2010N potential aSCT recipients. Cited reasons include concerns for patients with primary immunodeficiency syndromes and a misperception that TTI\u2010CMV is a \u2018never event\u2019. Furthermore, 17.9% of centres continue to provide CMV\u2010N components contrary to SaBTO recommendations, citing risks of CMV disease in primary immunodeficiency syndromes, resolution of ambiguous CMV serostatus, and HIV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adherence to SaBTO guidance on transfusion of CMV\u2010U blood components to aSCT recipients continues to improve, but further changes are likely to be challenging, based on the survey responses received and may require international collaboration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/tme.70014","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T03:26:49Z","timestamp":1758166009000},"page":"587-592","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["<scp>Cytomegalovirus<\/scp>\n                    \u2010selected blood components in allogeneic stem cell transplantation: A follow\u2010up survey of\n                    <scp>English<\/scp>\n                    transplant centre practices"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3413-1343","authenticated-orcid":false,"given":"Oliver","family":"Firth","sequence":"first","affiliation":[{"name":"Transfusion Medicine NHS Blood and Transplant  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-3223","authenticated-orcid":false,"given":"Suzy","family":"Morton","sequence":"additional","affiliation":[{"name":"Transfusion Medicine NHS Blood and Transplant  Birmingham UK"},{"name":"University Hospitals Birmingham NHS Foundation Trust  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41579\u2010021\u201000582\u2010z"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12437"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0955\u20103886(99)00089\u20102"},{"key":"e_1_2_10_5_1","unstructured":"UK Government.Cytomegalovirus tested blood components position statement.2012https:\/\/www.gov.uk\/government\/publications\/sabto-report-of-the-cytomegalovirus-steering-group"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12461"},{"key":"e_1_2_10_7_1","unstructured":"NarayanS PolesD Serious Hazards of Transfusion (SHOT) Steering Group.The annual SHOT report.2013https:\/\/www.shotuk.org\/shot-reports\/"},{"key":"e_1_2_10_8_1","unstructured":"Electronic Medicines Compendium (EMC).Summary of Product Characteristics\u2014Letermovir.https:\/\/www.medicines.org.uk\/emc\/product\/11943\/smpc"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17754"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2005.02.002"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2450\/2020.0241\u201019"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423\u20100410.2009.01306.x"},{"key":"e_1_2_10_13_1","unstructured":"NHS Improvement.Never Events list 2018.https:\/\/www.england.nhs.uk\/wp\u2010content\/uploads\/2020\/11\/2018\u2010Never\u2010Events\u2010List\u2010updated\u2010February\u20102021.pdf"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471\u20100528.14836"},{"key":"e_1_2_10_15_1","unstructured":"OlavarriaE.BSBMTCT yearly activity data.2025https:\/\/bsbmtct.org\/"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.11.016"},{"key":"e_1_2_10_17_1","unstructured":"AndersonM BaylissE BevanH et al.Sustainable improvement team: the change model guide.https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2018\/04\/change-model-guide-v5.pdf"}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.70014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T03:34:06Z","timestamp":1766460846000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tme.70014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/tme.70014"],"URL":"https:\/\/doi.org\/10.1111\/tme.70014","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"2025-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}